A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Masahiro TakadaShigeru ImotoTakanori IshidaYoshinori ItoHiroji IwataNorikazu MasudaHirofumi MukaiShigehira SajiTakafumi IkedaHironori HagaToshiaki SaekiKenjiro AogiTomoharu SugieTakayuki UenoShinji OhnoHiroshi IshiguroChizuko KanbayashiTakeshi MiyamotoYasuhiro HagiwaraMasakazu ToiPublished in: Breast cancer research and treatment (2023)
The benefit of adding adjuvant S-1 was particularly marked in group 2. Further investigations are warranted to explore the optimal usage of adjuvant S-1.